Literature DB >> 18024533

Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve.

Nancy R Cook1.   

Abstract

BACKGROUND: Diagnostic and prognostic or predictive models serve different purposes. Whereas diagnostic models are usually used for classification, prognostic models incorporate the dimension of time, adding a stochastic element. CONTENT: The ROC curve is typically used to evaluate clinical utility for both diagnostic and prognostic models. This curve assesses how well a test or model discriminates, or separates individuals into two classes, such as diseased and nondiseased. A strong risk predictor, such as lipids for cardiovascular disease, may have limited impact on the area under the curve, called the AUC or c-statistic, even if it alters predicted values. Calibration, measuring whether predicted probabilities agree with observed proportions, is another component of model accuracy important to assess. Reclassification can directly compare the clinical impact of two models by determining how many individuals would be reclassified into clinically relevant risk strata. For example, adding high-sensitivity C-reactive protein and family history to prediction models for cardiovascular disease using traditional risk factors moves approximately 30% of those at intermediate risk levels, such as 5%-10% or 10%-20% 10-year risk, into higher or lower risk categories, despite little change in the c-statistic. A calibration statistic can asses how well the new predicted values agree with those observed in the cross-classified data.
SUMMARY: Although it is useful for classification, evaluation of prognostic models should not rely solely on the ROC curve, but should assess both discrimination and calibration. Risk reclassification can aid in comparing the clinical impact of two models on risk for the individual, as well as the population.

Entities:  

Mesh:

Year:  2007        PMID: 18024533     DOI: 10.1373/clinchem.2007.096529

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  212 in total

1.  Screening for prostate cancer using multivariate mixed-effects models.

Authors:  Christopher H Morrell; Larry J Brant; Shan Sheng; E Jeffrey Metter
Journal:  J Appl Stat       Date:  2012-06-01       Impact factor: 1.404

Review 2.  Personalized medicine: hope or hype?

Authors:  Keyan Salari; Hugh Watkins; Euan A Ashley
Journal:  Eur Heart J       Date:  2012-06-01       Impact factor: 29.983

3.  Pre-diagnostic levels of adiponectin and soluble vascular cell adhesion molecule-1 are associated with colorectal cancer risk.

Authors:  Mathilde Touvier; Léopold Fezeu; Namanjeet Ahluwalia; Chantal Julia; Nathalie Charnaux; Angela Sutton; Caroline Méjean; Paule Latino-Martel; Serge Hercberg; Pilar Galan; Sébastien Czernichow
Journal:  World J Gastroenterol       Date:  2012-06-14       Impact factor: 5.742

4.  Deep phenotyping to predict live birth outcomes in in vitro fertilization.

Authors:  Prajna Banerjee; Bokyung Choi; Lora K Shahine; Sunny H Jun; Kathleen O'Leary; Ruth B Lathi; Lynn M Westphal; Wing H Wong; Mylene W M Yao
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

5.  Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT).

Authors:  Douglas G Manuel; Meltem Tuna; Carol Bennett; Deirdre Hennessy; Laura Rosella; Claudia Sanmartin; Jack V Tu; Richard Perez; Stacey Fisher; Monica Taljaard
Journal:  CMAJ       Date:  2018-07-23       Impact factor: 8.262

6.  Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients.

Authors:  Francesca Mallamaci; Giovanni Tripepi; Graziella D'Arrigo; Silvio Borrelli; Carlo Garofalo; Giovanna Stanzione; Michele Provenzano; Luca De Nicola; Giuseppe Conte; Roberto Minutolo; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-02       Impact factor: 8.237

7.  Frailty and mortality: 'Same-same but Different'.

Authors:  Sei J Lee
Journal:  BMJ Qual Saf       Date:  2019-01-03       Impact factor: 7.035

Review 8.  Genetic profiling and individualized assessment of fracture risk.

Authors:  Tuan V Nguyen; John A Eisman
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

9.  Evaluation of models for predicting the probability of malignancy in patients with pulmonary nodules.

Authors:  You Li; Hui Hu; Ziwei Wu; Ge Yan; Tangwei Wu; Shuiyi Liu; Weiqun Chen; Zhongxin Lu
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

10.  Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts.

Authors:  D S Cross; C A McCarty; E Hytopoulos; M Beggs; N Nolan; D S Harrington; T Hastie; R Tibshirani; R P Tracy; B M Psaty; R McClelland; P S Tsao; T Quertermous
Journal:  Curr Med Res Opin       Date:  2012-11       Impact factor: 2.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.